Entecavir plus tenofovir combination therapy in patients with multidrug‐resistant chronic hepatitis B: results of a multicentre, prospective study
Adult
Male
Hepatitis B virus
Guanine
Drug Resistance
610
Viral/blood
Antiviral Agents
Antiviral Agents/administration & dosage*
Drug Administration Schedule
combination therapy
03 medical and health sciences
Hepatitis B, Chronic
Drug Therapy
Drug Resistance, Multiple, Viral
Chronic/drug therapy*
616
Republic of Korea
Guanine/analogs & derivatives*
Humans
chronic hepatitis B
Prospective Studies
Viral/drug effects
Tenofovir
0303 health sciences
Guanine/administration & dosage
multidrug resistant
DNA
Tenofovir/administration & dosage*
Middle Aged
Hepatitis B virus/genetics
Hepatitis B
tenofovir
3. Good health
Hepatitis B virus/drug effects
Treatment Outcome
Combination
DNA, Viral
Drug Therapy, Combination
Female
Multiple
entecavir
DOI:
10.1111/liv.13059
Publication Date:
2016-01-19T13:27:08Z
AUTHORS (8)
ABSTRACT
AbstractBackground & AimsSequential therapy posed a high risk of emergence of multidrug resistance and presented a management issue in chronic hepatitis B (CHB) treatment. We evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug‐resistant (MDR) CHB patients.MethodsIn this prospective, multicentre study, MDR CHB patients, defined as measurable serum HBV DNA (≥60 IU/ml) while on any rescue treatment regimen for at least 24 weeks and the presence of documented prior genotypic resistance to both nucleoside analogue(s) and nucleotide analogue, were treated with ETV 1.0 mg and TDF 300 mg combination therapy for 48 weeks.ResultsA total of 64 eligible patients who had previously failed to a median three lines of antiviral therapy (range, 2–6) were included. At baseline, median age was 47.0 years, 89.1% were HBeAg(+), and median HBV DNA was 4.24 (range, 2.11–6.73) log10 IU/ml. By week 4, 12, 24 and 48, 15/64 (23.4%), 36/64 (56.3%), 43/64 (67.2%) and 55/64 (85.9%) patients achieved a HBV DNA <60 IU/ml respectively. The mean reduction of HBV DNA from baseline to 4 and 48 weeks was 1.23 log10 IU/ml and 2.38 log10 IU/ml respectively. Although five patients experienced virological breakthrough, all were transient and no resistant mutation to TDF or novel mutation was detected in any patients.ConclusionsIn difficult‐to‐treat MDR CHB patients with a high exposure to multiple antiviral drugs, ETV plus TDF combination therapy can provide a very high rate of viral suppression through 48 weeks of treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (25)
CITATIONS (18)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....